Health · July 30, 2026 · 8 min read
How GLP-1 sourcing works in 2026 — and how to stay safe
GLP-1 sourcing looks very different than it did two years ago. Here is the new legal landscape and why licensed pharmacies matter more than ever.
Two years ago, getting a GLP-1 for weight management often meant a compounded version of semaglutide from a specialty pharmacy at a fraction of the brand-name price — legal because the FDA had temporarily allowed compounding while brand-name supply fell short of demand. Then the manufacturers caught up, the shortages ended, and the rules changed. Here is what the landscape looks like now, and what it means for you as a patient.
A quick history lesson
When an FDA-approved drug is in short supply, it goes on the FDA's "shortage list," and specialty pharmacies are allowed to prepare custom versions so patients do not go without. Semaglutide and tirzepatide entered that list in 2022 as demand outpaced production, and compounded versions grew to roughly 30% of all GLP-1s in the country — often around $200 a month versus $1,000 or more for branded products.
Then supply caught up. The FDA resolved the tirzepatide shortage in October 2024 and the semaglutide shortage in February 2025, and the legal pathway for routine compounded copies narrowed significantly. In April 2026 the agency proposed permanently closing the larger-scale outsourcing pathway for these drugs as well.
The four ways GLP-1s reach patients today
1. Branded, FDA-approved products. Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, and Victoza — the most straightforward path with the least regulatory ambiguity. A licensed clinician evaluates you, writes a prescription, and it is filled at a retail or specialty pharmacy. Out-of-pocket cost runs about $1,000 to $1,400 per month without insurance or manufacturer savings programs.
2. 503A compounding pharmacies. State-licensed pharmacies that prepare medications one prescription at a time. They can still make a custom version of semaglutide or tirzepatide when there is a documented medical reason you cannot take the brand-name product — an allergy to an inactive ingredient, or a dose strength the manufacturer does not make. What they can no longer do is make routine copies at scale simply because they are cheaper.
3. 503B outsourcing facilities. Larger-scale pharmacies registered directly with the FDA under stricter quality and sterility standards. This route is in regulatory transition — the FDA's April 2026 proposal would close it for GLP-1s if finalized — so these pharmacies are still supplying today, but likely not for much longer.
4. Research-grade peptides. The dangerous one. These are sold online under "for research only" labels by overseas websites, Telegram channels, and social media accounts that disappear and reappear under new names. Nothing about the product is regulated — not the ingredients, the dose, the sterility, or who made it. The FDA has documented vials containing the wrong active ingredient (including salt forms of semaglutide never tested in humans), doses far above the safe range, contamination, and outright counterfeits labeled to look like real Ozempic. Our approach is simple: steer clear entirely.
What a safe supply chain looks like
A trustworthy pharmacy is state-licensed everywhere it dispenses, sources raw ingredients from FDA-registered manufacturers, tests every product for potency, sterility, and contamination (with certificates of analysis to prove it), and requires real prescriber documentation. If a provider hesitates on any of those points, keep looking.
When evaluating any program that offers GLP-1s, ask: Do you source from licensed compounding pharmacies or "research use only" vendors? Can you provide certificates of analysis on request? Is the clinical team board-certified, and licensed in my state?
Frequently asked questions
Is compounded semaglutide still allowed in 2026? Yes, with limitations — when there is a documented medical reason a patient cannot take the brand-name version. Routine custom copies at scale, made simply because they are cheaper, are no longer permitted. This is not legal advice; the rules continue to evolve.
What is the difference between a 503A pharmacy and a 503B facility? Both prepare custom medications at different scales under different rules. A 503A is state-licensed and works one patient prescription at a time; a 503B is registered directly with the FDA, produces in bulk, and operates under stricter quality requirements.
Who can prescribe GLP-1s? Only licensed clinicians — typically a physician, nurse practitioner, or physician assistant depending on state law. Any program offering GLP-1s without a licensed prescriber involved is operating outside the law.
What is the cost difference between branded and compounded? Significant. Branded products run about $1,000 to $1,400 per month at retail; compounded versions historically ranged from $150 to $400. That price gap is why the compounded market exploded — and why the tightening rules matter so much to patients.
Rise Wellness and Longevity protocols are prescribed by board-certified physicians and dispensed exclusively through licensed 503A and 503B pharmacies to USP standards — no gray market, no research-use-only material. Whatever the FDA decides next, that supply chain does not change.
Sources
- Frequently Asked Questions about Drug Shortages — FDA
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — FDA
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — FDA
Adapted for Rise Wellness and Longevity from reporting originally published by Altro Health. Educational content only; not medical advice.